OncoTalks | Oncology Insights at Your Fingertips
af Ontada Learn
R/R LBCL: A Practical Guide to CAR T Referral and Coordination
Om denne podcast
OncoTalks is the podcast for community oncology providers and clinicians who want to stay on top of new treatments and the latest advancements in oncology. Join Ontada Learn and community oncologists from The US Oncology Network as they explore oncology with a focus on the latest breakthroughs in cancer care. Expect concise, impactful discussions with practical clinical insights tailored for the real-world community oncology setting.
Additionally, don’t miss OncoTalks Case Journeys, where experts deep dive into oncology patient cases and treatment journeys. Join as they conduct comprehensive case reviews, explore key learnings, and discuss the latest research and advances related to each case.
Tune into OncoTalks and start unlocking pathways to better patient care today!
Episoder
De nyeste 20 af 47 episoder
- R/R LBCL: A Practical Guide to CAR T Referral and Coordination · 10 min. · Episode 50In this episode, Drs. Loretta Nastoupil and Manali Kamdar sit down to discuss the evolving role of CAR T-cell therapy in relapsed or refractory LBCL, including patient…
- Micro-Series | Part 4 | Beyond Breast Cancer Treatment Selection: Supporting Adherence and Quality of Life · 4 min. · Episode 55In this concluding episode, Dr. Mabel Mardones shares practical approaches to managing treatment-related toxicities, supporting adherence, and maintaining quality of life…
- Micro-Series | Part 3 | Biomarker-Driven Treatment Sequencing in Metastatic Breast Cancer · 4 min. · Episode 54In this episode of OncoTalks, Dr. Mabel Mardones examines how endocrine sensitivity, biomarker testing, and evolving resistance biology inform treatment sequencing in metastatic…
- Micro-Series | Part 2 | Choosing a CDK4/6 Inhibitor in Early-Stage Breast Cancer · 5 min. · Episode 53In this episode of OncoTalks, Dr. Mabel Mardones explains how treatment duration, toxicity profiles, and patient-specific factors can inform CDK4/6 inhibitor selection in…
- Micro-Series | Part 1 | Personalizing Treatment in Early-Stage HR+/HER2− Breast Cancer · 4 min. · Episode 52In this episode of OncoTalks, Dr. Mabel Mardones discusses how clinical features, genomic risk, and patient priorities inform treatment planning in early-stage…
- Evolving CLL Care: What Long-Term Data Teach Us About BTK Inhibitors · 13 min. · Episode 51In this episode of OncoTalks, host Dr. Ira Zackon welcomes Dr. Brad Christensen to discuss how mature clinical trial data are influencing treatment selection and patient…
- Long-Term BTKi Success: Adherence, Dosing, and Patient Support in CLL · 16 min. · Episode 49Adherence starts long before the first missed dose. In this episode, Dr. Brad Christensen shares real-world insights on helping patients with chronic lymphocytic leukemia (CLL)…
- Micro-Series | Part 4 | Optimizing Long-Term TKI Therapy in Resistant CML · 4 min. · Episode 48In the final installment, Dr. Luke Fletcher shares strategies for managing resistant chronic myeloid leukemia (CML), including adverse event monitoring, supportive care, and…
- Micro-Series | Part 3 | Managing Resistance in CML: When and Why to Test for BCR-ABL1 Mutations · 4 min. · Episode 47Dr. Luke Fletcher discusses mutation testing in chronic myeloid leukemia (CML), including when to test, how results influence treatment decisions, and the clinical significance…
- Micro-Series | Part 2 | Measuring Molecular Response in Ph+ ALL · 4 min. · Episode 46Dr. Luke Fletcher examines the growing role of measurable residual disease (MRD) and molecular response in treatment monitoring, and the impact of tyrosine kinase inhibitor (TKI)…
- Micro-Series | Part 1 | TKIs in Frontline Ph+ ALL Treatment · 4 min. · Episode 45Dr. Luke Fletcher reviews the evolving treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), highlighting how tyrosine kinase inhibitors…
- Micro-Series | Part 4 | The Next Evolution in Anti-CD38 Therapy: On-Body Injector Technology · 4 min. · Episode 43Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy…
- Micro-Series | Part 3 | The Nursing Perspective on Subcutaneous Anti-CD38 Therapy · 5 min. · Episode 42Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations…
- Micro-Series | Part 2 | Frontline Treatment Optimization in High-Risk and Transplant-Ineligible Multiple Myeloma · 4 min. · Episode 41Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life…
- Micro-Series | Part 1 | Navigating Care for Transplant-Ineligible Multiple Myeloma Patients · 4 min. · Episode 40Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly…
- HER2 Testing in Solid Tumors · 1 min. · Episode 44This learning module provides a brief overview of HER2 testing in metastatic non-small cell lung, bladder, rectal, cervical, biliary tract, ovarian, pancreatic, endometrial, and…
- Provider Perspectives on BTKi Selection in CLL · 12 min. · Episode 39In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of…
- Navigating the CLL Treatment Landscape: The Role of Physician Choice · 8 min. · Episode 38In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL)…
- Case Journey | EP-NEC in Focus: A Case-Based Look at Unmet Needs and DLL3-Targeted Therapy · 8 min. · Episode 37Follow the clinical journey of extrapulmonary neuroendocrine carcinoma (EP-NEC) through a real-world patient case presented by Dr. Deepak Bhamidipati. This episode explores key…
- Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus · 5 min. · Episode 36Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Meredith Pelster discusses the biology behind DLL3 overexpression and the latest…








